Literature DB >> 18931138

Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.

Judit Morello1, Sonia Rodríguez-Novoa, Inmaculada Jiménez-Nácher, Vincent Soriano.   

Abstract

Ribavirin in combination with pegylated interferon alpha is the current standard treatment for chronic hepatitis C. Adequate exposure to ribavirin seems crucial for achieving the best virological response. However, anaemia is a frequent, dose-dependent limiting side effect of ribavirin use. Therefore, therapeutic drug monitoring of ribavirin plasma concentrations could be a useful tool for individualizing ribavirin dosing. Herein, we review the relationship between ribavirin plasma concentrations and both virological response and toxicity, in order to define an optimal therapeutic range for ribavirin.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18931138     DOI： 10.1093/jac/dkn421

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  23 in total

1.  Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.

Authors:  Cédric Laouénan; Patrick Marcellin; Martine Lapalus; Feryel Khelifa-Mouri; Nathalie Boyer; Fabien Zoulim; Lawrence Serfaty; Jean-Pierre Bronowicki; Michelle Martinot-Peignoux; Olivier Lada; Tarik Asselah; Céline Dorival; Christophe Hézode; Fabrice Carrat; Florence Nicot; Gilles Peytavin; France Mentré; Jeremie Guedj
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

2.  ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor?

Authors:  Laura Milazzo; Dario Cattaneo; Stefania Cheli; Laurenzia Ferraris; Elisa Colella; Emilio Clementi; Cristina Gervasoni
Journal:  Eur J Clin Pharmacol       Date:  2012-09-19       Impact factor: 2.953

Review 3.  A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.

Authors:  Girish S Naik; Manoj G Tyagi
Journal:  J Clin Exp Hepatol       Date:  2012-04-12

4.  Controversies' clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages.

Authors:  George D Liatsos
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

Review 5.  Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Ahmed Ashshi; Esam Azhar
Journal:  Int J Clin Exp Med       Date:  2015-07-15

6.  Mycophenolate mofetil may induce prolonged severe anemia during pegylated-interferon/ribavirin/simeprevir therapy in liver transplant recipients.

Authors:  Tomomi Kogiso; Katsutoshi Tokushige; Etsuko Hashimoto; Makiko Taniai; Akiko Omori; Yoshihito Kotera; Hiroto Egawa; Masakazu Yamamoto; Keiko Shiratori
Journal:  Clin J Gastroenterol       Date:  2015-05-12

7.  Ribavirin induced anaemia: the effect of vitamin D supplementation on erythropoietin and erythrocyte indices in normal Wistar rat.

Authors:  Bassem Refaat; Tariq Helal Ashour; Adel Galal El-Shemi
Journal:  Int J Clin Exp Med       Date:  2014-09-15

8.  Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment.

Authors:  B J Brennan; K Wang; S Blotner; M O Magnusson; J J Wilkins; P Martin; J Solsky; K Nieforth; C Wat; J F Grippo
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

9.  Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C.

Authors:  Judit Morello; Vincent Soriano; Pablo Barreiro; José Medrano; Antonio Madejón; Gema González-Pardo; Inmaculada Jiménez-Nácher; Juan González-Lahoz; Sonia Rodríguez-Novoa
Journal:  Antimicrob Agents Chemother       Date:  2010-01-25       Impact factor: 5.191

Review 10.  COVID-19: Vaccine Delivery System, Drug Repurposing and Application of Molecular Modeling Approach.

Authors:  Soha R Abd El Hadi; Esmat E Zien El-Deen; Mostafa M Bahaa; Abdelfattah A Sadakah; Heba A Yassin
Journal:  Drug Des Devel Ther       Date:  2021-07-30       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.